BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38368742)

  • 21. How does the mitotic index impact patients with T1 melanoma? Comparison between the 7th and 8th edition of the American Joint Committee on Cancer melanoma staging system.
    Antonialli AZ; Bertolli E; de Macedo MP; Pinto CAL; Calsavara VF; Neto JPD
    An Bras Dermatol; 2020; 95(6):691-695. PubMed ID: 33008658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
    Eroglu Z; Broman KK; Thompson JF; Nijhuis A; Hieken TJ; Kottschade L; Farma JM; Hotz M; Deneve J; Fleming M; Bartlett EK; Sharma A; Dossett L; Hughes T; Gyorki DE; Downs J; Karakousis G; Song Y; Lee A; Berman RS; van Akkooi A; Stahlie E; Han D; Vetto J; Beasley G; Farrow NE; Hui JYC; Moncrieff M; Nobes J; Baecher K; Perez M; Lowe M; Ollila DW; Collichio FA; Bagge RO; Mattsson J; Kroon HM; Chai H; Teras J; Sun J; Carr MJ; Tandon A; Babacan NA; Kim Y; Naqvi M; Zager J; Khushalani NI
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.
    Esmaeli B; Rubin ML; Xu S; Goepfert RP; Curry JL; Prieto VG; Ning J; Tetzlaff MT
    Am J Surg Pathol; 2019 Dec; 43(12):1701-1710. PubMed ID: 31425167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma.
    LeBlanc RE; Barton DT; Li Z; Angeles CV; Ernstoff MS; Bagley E; Wimmer D; Wong SL; Barth RJ; Shirai K; Yan S
    Am J Surg Pathol; 2019 Jun; 43(6):755-765. PubMed ID: 31091203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsatellitosis in Patients with Melanoma.
    Karakousis GC; Gimotty PA; Leong SP; Pockaj BA; White RL; O'Donoghue C; Sinnamon AJ; Bartlett EK; Dueck AC; Gould Rothberg BE; Messina JL; Vetto JT; Sondak VK; Schneebaum S; Kashani-Sabet M; Han D; Faries MB; Zager JS;
    Ann Surg Oncol; 2019 Jan; 26(1):33-41. PubMed ID: 30421045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?
    Rios-Cantu A; Lu Y; Melendez-Elizondo V; Chen M; Gutierrez-Range A; Fadaki N; Thummala S; West-Coffee C; Cleaver J; Kashani-Sabet M; Leong SPL
    Clin Exp Metastasis; 2017 Jun; 34(5):345-350. PubMed ID: 28699042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1-2 and cN0 breast cancer.
    Shigematsu H; Nishina M; Yasui D; Hirata T; Ozaki S
    World J Surg Oncol; 2019 Feb; 17(1):41. PubMed ID: 30797231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients.
    Gambichler T; Scholl L; Bechara FG; Stockfleth E; Stücker M
    Eur J Surg Oncol; 2016 Sep; 42(9):1420-6. PubMed ID: 27160354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study.
    Beasley GM; Hu Y; Youngwirth L; Scheri RP; Salama AK; Rossfeld K; Gardezi S; Agnese DM; Howard JH; Tyler DS; Slingluff CL; Terando AM
    Ann Surg Oncol; 2017 Sep; 24(9):2728-2733. PubMed ID: 28508145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8
    Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM
    J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter Adoption and Outcomes of Nodal Observation for Patients with Melanoma and Sentinel Lymph Node Metastases.
    Parvez E; Khosrow-Khavar F; Dumitra T; Nessim C; Bernard-Bédard É; Rivard J; Pravong V; Wang S; Gervais MK; Meterissian S; Dumitra S
    Ann Surg Oncol; 2023 Feb; 30(2):1195-1205. PubMed ID: 36282456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?
    Han D; Han G; Morrison S; Leong SP; Kashani-Sabet M; Vetto J; White R; Schneebaum S; Pockaj B; Mozzillo N; Sondak VK; Zager JS
    Surgery; 2020 Sep; 168(3):518-526. PubMed ID: 32669204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
    Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
    J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histological regression in melanoma: impact on sentinel lymph node status and survival.
    Aivazian K; Ahmed T; El Sharouni MA; Stretch JR; Saw RPM; Spillane AJ; Shannon KF; Ch'ng S; Nieweg OE; Thompson JF; Lo SN; Scolyer RA
    Mod Pathol; 2021 Nov; 34(11):1999-2008. PubMed ID: 34247192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitotic rate as a predictive factor for positive sentinel lymph nodes in pT1 and pT2 melanomas.
    Fidanzi C; Bevilacqua M; D'Erme AM; Morganti R; Viacava P; Manzo Margiotta F; Romanelli M; Dini V; Janowska A; Bagnoni G
    J Plast Reconstr Aesthet Surg; 2023 Aug; 83():215-220. PubMed ID: 37279633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.
    Rousseau DL; Ross MI; Johnson MM; Prieto VG; Lee JE; Mansfield PF; Gershenwald JE
    Ann Surg Oncol; 2003 Jun; 10(5):569-74. PubMed ID: 12794025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
    Tas F; Erturk K
    Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.